Overview

Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety after 12 weeks oral administration of Imidafenacin 0.1mg b.i.d versus Fesoterodine 4mg once daily for the urge incontinence and/or increased urinary frequency associated with urgency as may occur in patients with overactive bladder.
Phase:
Phase 4
Details
Lead Sponsor:
LG Life Sciences
Collaborator:
Kyorin Pharmaceutical Co.,Ltd
Treatments:
Fesoterodine